Pre-filled plasma half-life model for PT-141. See how a 2.7 hours half-life affects steady state, accumulation, peak-trough swing, and clearance timing.
Preset values: 1750 mcg every day, half-life ~2.7 hours.
~2.7h half-life (Vyleesi label, range 1.9–4h). Used on demand at least 45 min before activity and no more than once in 24h; after 24h about 0.2% of a dose remains, so nothing accumulates.
Open interactive chart →The half-life used here (2.7 hours) is the published or well-established estimate for PT-141 from pharmacokinetic studies. The default dose (1750 mcg) and cadence (every day) reflect typical standard protocols — not a prescription or recommendation. Your specific product's label and your clinician's protocol override any default here.
Accumulation. With a half-life of 2.7 hours and dosing every day, the ratio τ/t½ = 8.89 gives an accumulation factor of ~1.00×. That means the steady-state peak plasma mass is about 1.0× the mass of a single dose.
Time to steady state. Approximately 5 half-lives (~0.6 days) of consistent dosing before average concentration stops rising. Dose-escalation protocols that change doses before this point are titrating against a still-rising baseline, which is one reason weekly peptides feel "slow" at the start.
After a single dose, half of the PT-141 is gone in about 2.7 hours, 97% is cleared in about 14 hours (five half-lives), and under 1% remains after about 18 hours.
| Cleared | Remaining | Half-lives | Time after one PT-141 dose |
|---|---|---|---|
| 50% | 50% | 1 | 2.7 hours |
| 75% | 25% | 2 | 5.4 hours |
| 90% | 10% | 3.3 | 9 hours |
| 97% | 3% | 5.1 | 14 hours |
| 99% | 1% | 6.6 | 18 hours |
Between doses. At every day, doses land 8.89 half-lives apart, so about 0.2% of the peak is still present when the next dose goes in. The steady-state swing in this model runs from ~1754 mcg at peak to ~3.7 mcg at trough — a pulse that mostly clears before the next injection, so PT-141 does not build up much at this cadence.
A first-order, one-compartment model: it leaves out absorption delay from the injection depot, protein binding and individual differences in clearance, and effects can outlast plasma levels. Good for dosing rhythm; not clinical pharmacokinetics.
This chart uses an estimated PT-141 plasma half-life of about 2.7 hours. Published values can vary by formulation, route, assay, and study design.
A simple first-order model reaches practical steady state after about five half-lives, which is roughly 14 hours for PT-141.
After a single dose, half of the PT-141 is gone in about 2.7 hours, 97% is cleared in about 14 hours (five half-lives), and under 1% remains after about 18 hours. Those are plasma estimates from a half-life of 2.7 hours; effects can outlast plasma levels, and detection windows depend on the assay.
Dosing every day is 8.89 half-lives apart, so about 0.2% of the peak level remains at the next dose. At steady state that means a peak of ~1754 mcg and a trough of ~3.7 mcg in the model.
No. It visualizes half-life, accumulation, peaks, and troughs from values you enter. It is not a prescription, dose recommendation, or substitute for the product label or clinician guidance.
Steady state explains why long-half-life compounds can keep rising for weeks after starting or changing a dose, while short-half-life compounds behave more like brief pulses.
Peptide Protocol logs every actual injection time and shows your real timeline — not a model. Side-effect tracking included.
Get the iPhone app →Educational use only. Nothing on this page constitutes medical advice. Pharmacokinetic parameters are published estimates; individual PK varies. Use label values and consult a clinician for any dosing decision.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.